ZyVersa Therapeutics reported revenue of -$0.13M and net income of -$1.30M for the quarter ended Mar 2026, down 10.8% year over year. This income statement covers 16 quarters of results from Mar 2022 through Mar 2026, standardized by Business Quant from the company’s SEC filings.
| Income StatementIncome Statement | Mar2022 | Jun2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | ||||||||||||||||
| Revenue | -0.17M | -0.14M | 0.00M | -314.00 | -210.00 | -98.00 | -101.00 | -58.00 | -0.13M | -0.14M | -0.12M | -0.13M | -0.13M | -0.13M | -0.13M | |
| Operating items | ||||||||||||||||
| Research & DevelopmentR&D | 1.07M | 0.72M | 1.06M | 1.22M | 0.67M | 0.26M | 0.51M | 0.71M | 0.44M | 0.12M | 0.26M | 0.41M | 0.37M | 0.08M | 0.06M | |
| Selling, General & AdministrativeSG&A | 2.30M | 1.16M | 3.54M | 3.93M | 2.23M | 1.52M | 2.31M | 2.04M | 1.83M | 1.17M | 1.89M | 1.63M | 1.74M | 0.47M | 1.25M | |
| Other Operating ExpensesOther Opex | 0.08M | 0.11M | 81.18M | 12.16M | 18.65M | |||||||||||
| Operating ExpensesOpex | 0.80M | 0.50M | 4.59M | 86.33M | 2.90M | 13.93M | 2.83M | 2.75M | 2.27M | 1.29M | 2.14M | 2.04M | 20.75M | 0.55M | 1.30M | |
| Operating IncomeOp. Inc | -0.80M | -0.50M | -4.59M | -86.33M | -2.90M | -13.93M | -2.83M | -2.75M | -2.27M | -1.29M | -2.14M | -2.04M | -20.75M | -0.55M | -1.30M | |
| EBIT | -0.80M | -0.50M | -4.59M | -86.33M | -2.90M | -13.93M | -2.83M | -2.75M | -2.27M | -1.29M | -2.14M | -2.04M | -20.75M | -0.55M | -1.30M | |
| Non-operating items | ||||||||||||||||
| Goodwill impairment chargesGoodwill Impair. | 11.90M | |||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.08M | -0.02M | ||||||||||||||
| Net income details | ||||||||||||||||
| EBT | -0.80M | -2.00M | -4.59M | -86.33M | -2.90M | -13.93M | -2.83M | -2.75M | -2.40M | -1.42M | -2.14M | -2.21M | -20.66M | -0.68M | -1.30M | |
| Tax ProvisionsTaxes | -1.05M | -7.81M | -485.00 | -0.60M | 0.01M | 0.00M | -0.85M | |||||||||
| Profit After TaxPAT | -0.80M | -2.00M | -3.54M | -78.51M | -2.90M | -13.34M | -2.83M | -2.76M | -2.40M | -1.42M | -2.14M | -2.21M | -19.81M | -0.68M | -1.30M | |
| Income from Continuing OperationsIncome (Continuing) | -0.80M | -2.00M | -3.54M | -78.51M | -2.90M | -13.34M | -2.83M | -2.76M | -2.40M | -1.42M | -2.14M | -2.21M | -19.81M | -0.68M | -1.30M | |
| Consolidated Net IncomeConsol Net Inc. | -0.80M | -2.00M | -3.54M | -78.51M | -2.90M | -13.34M | -2.83M | -2.76M | -2.40M | -1.42M | -2.14M | -2.21M | -19.81M | -0.68M | -1.30M | |
| Income towards Parent CompanyParent Net Inc | -0.72M | -0.39M | -3.54M | -78.51M | -2.90M | -13.34M | -2.83M | -2.76M | -2.40M | -1.42M | -2.26M | -2.21M | -19.81M | -0.70M | -1.80M | |
| Preferred Dividend PaymentsPref Dividends | 0.33M | 7.92M | 0.03M | |||||||||||||
| Net Income towards Common StockholdersNet Income | -0.72M | -2.34M | -3.54M | -86.43M | -2.93M | -13.34M | -2.83M | -2.76M | -2.40M | -1.42M | -2.26M | -2.21M | -19.81M | -0.70M | -1.80M | |
| Additional items | ||||||||||||||||
| EPS (Basic) | -31.22 | -101.07 | -135.89 | 0.00M | -33.16 | -136.80 | -4.53 | -3.31 | -2.43 | -1.28 | -0.73 | -0.46 | -2.56 | -0.12 | -0.22 | |
| EPS (Diluted) | -134.40 | -101.07 | -135.88 | 0.00M | -33.16 | -136.80 | -4.53 | -3.31 | -2.43 | -1.28 | -0.73 | -0.46 | -2.56 | -0.12 | -0.22 | |
| Shares Outstanding | 0.02M | 0.02M | 0.03M | 0.03M | 0.05M | 0.09M | 0.10M | 0.62M | 0.83M | 0.99M | 1.11M | 3.11M | 4.81M | 7.74M | 5.96M | 8.10M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 0.01M | 0.02M | 0.03M | 0.03M | 0.05M | 0.09M | 0.10M | 0.62M | 0.83M | 0.99M | 1.11M | 3.11M | 4.81M | 7.74M | 5.96M | 8.10M |
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 0.02M | 0.02M | 0.03M | 0.03M | 0.05M | 0.09M | 0.10M | 0.62M | 0.83M | 0.99M | 1.11M | 3.11M | 4.81M | 8.10M | 5.96M | 8.10M |
| EBITDA | -0.77M | -0.49M | -4.59M | -86.32M | -2.90M | -13.93M | -2.82M | -2.75M | -2.27M | -1.29M |
Pull ZyVersa Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=ZVSA&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "ZVSA", "statement": "IS", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=ZVSA&statement=IS&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();